Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 124 Results

Title
Intervention Indication Therapeutic Area Year Actions
Treosulfan in combination with Fludarabine for Malignant and Non-Malignant diseases - prior to stem cell transplantation Fludarabine (fludarabine phosphate) , Treosulfan (Ovastat) Acute myeloid leukaemia (AML) , Myelodysplastic syndrome (MDS) Haematological Cancer and Lymphomas 2018 View  |  Download
Ublituximab (TG-1101) in combination with umbralisib (TGR-1202) for chronic lymphocytic leukaemia Ublituximab (TG-1101; LFB-R603) , Umbralisib (TGR-1202; RP-5264) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2017 View  |  Download
Ublituximab in Combination with Ibrutinib for High Risk Chronic Lymphocytic Leukaemia Ibrutinib (Imbruvica) , Ublituximab (TG-1101; LFB-R603) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2018 View  |  Download
Venetoclax in addition to ibrutinib for relapsed mantle cell lymphoma – second-line and beyond Ibrutinib (Imbruvica) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Mantle cell lymphoma Haematological Cancer and Lymphomas 2020 View  |  Download
Venetoclax in combination with a hypomethylating agent or low dose cytarabine for newly diagnosed acute myeloid leukaemia hypomethylating agent , Low-dose cytarabine , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2018 View  |  Download
Venetoclax in combination with bortezomib and dexamethasone for relapsed multiple myeloma - second line and beyond Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Venetoclax in Combination with Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukaemia – First Line Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2017 View  |  Download
Venetoclax with dexamethasone for previously treated relapsed/refractory multiple myeloma Dexamethasone (dexamethasone sodium metasulfobenzoate) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2021 View  |  Download
Zamtocabtagene autoleucel for relapsed or refractory diffuse large B-cell lymphoma after at least 2 therapies Zamtocabtagene autoleucel Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma Zamtocabtagene autoleucel Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications